Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Fall on the Road
Home & Realty
Outdoor Guide
Women
Fall Home Improvement
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Services
2023 Readersâ Choice Winners
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Exelixis Inc
(NQ:
EXEL
)
21.05
-0.56 (-2.59%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 28, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Exelixis Inc
< Previous
1
2
3
4
5
6
7
Next >
Under the Microscope: 3 Biotech Stocks Pioneering Tomorrow’s Cures
November 09, 2023
Unveil the resilience of biotech stocks as they outsmart market trends and champion the race for tomorrow's treatments.
Via
InvestorPlace
3 Biotech Stocks With the Strongest Clinical Pipelines
November 08, 2023
Many industry heavyweights are on the hunt for fresh new ideas -- great news for biotech stocks to buy with strong pipelines.
Via
InvestorPlace
3 Promising Biotech Stocks Flying Under the Radar
November 08, 2023
Breakthroughs in healthcare are happening everyday, make sure you are keeping up to date on these under the radar biotech stocks.
Via
InvestorPlace
Looking for growth without the hefty price tag? Consider NASDAQ:EXEL.
November 06, 2023
EXELIXIS INC (NASDAQ:EXEL) is showing decent growth, but is still valued reasonably.
Via
Chartmill
Where Exelixis Stands With Analysts
November 02, 2023
Via
Benzinga
Exelixis (EXEL) Q3 2023 Earnings Call Transcript
November 02, 2023
EXEL earnings call for the period ending September 30, 2023.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Earnings Outlook For Exelixis
October 31, 2023
Via
Benzinga
Is Exelixis Stock a Buy Now?
October 18, 2023
There is one key reason to consider the stock.
Via
The Motley Fool
14 Analysts Have This to Say About Exelixis
October 11, 2023
Via
Benzinga
4 Dominant Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
October 28, 2023
Bargains abound for growth-seeking investors, with the Nasdaq Composite still 20% below its record-closing high.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
Why Exelixis Stock Is Trading Lower Today
October 23, 2023
Exelixis, Inc. (NASDAQ: EXEL) shares are trading lower on Monday after the company announced detailed results from its Phase 3 CABINET pivotal trial evaluating Cabozantinib in
Via
Benzinga
3 Under-the-Radar Biotech Stocks to Buy in 2023
October 19, 2023
These three lesser-known biotech companies are profitable and growing revenue.
Via
The Motley Fool
Don't overlook NASDAQ:EXEL—a stock with solid growth prospects and a reasonable valuation.
October 13, 2023
EXELIXIS INC (NASDAQ:EXEL) is showing good growth, while it is not too expensive.
Via
Chartmill
Steady Eddies: 3 Low Beta Stocks for Long-Haul Gains
October 02, 2023
Low-beta stocks provide an avenue for investors looking for long-term growth accompanied by low volatility.
Via
InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
September 29, 2023
Via
Benzinga
2 Top Biotech Stocks Defying the Bear Market
September 15, 2023
The best may be yet to come for these companies.
Via
The Motley Fool
The Latest Analyst Ratings for Exelixis
September 13, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 26, 2023
September 26, 2023
Via
Benzinga
3 Biotech Stocks That Should Be on Every Investor’s Radar This Fall
September 20, 2023
Even with higher for longer interest rates, drug discovery moves on. That’s why it’s still a good time to look for biotech stocks to buy.
Via
InvestorPlace
Week In Review: Hasten Signs $325 Million Deal For China Rights To PCSK9 Cholesterol Therapy
September 16, 2023
Hasten Biopharma entered a $325 million agreement for greater China rights to a PCSK9 inhibitor from LIB Therapeutics. Meanwhile, Insilico Medicine out-licensed global rights to a small molecule...
Via
Talk Markets
4 Magnificent Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
September 16, 2023
A 14% decline in the Nasdaq Composite represents the perfect opportunity for investors to pounce.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
Where Exelixis Stands With Analysts
August 22, 2023
Via
Benzinga
The Top Healthcare Stocks to Buy With $100
August 30, 2023
Both stocks have outperformed the broader market in the last 12 months.
Via
The Motley Fool
Exelixis' Lead Cancer Treatment Delivers Another Surprise, Though Analyst Finds Commercial Opportunity In Pancreatic Neuroendocrine Modest
August 24, 2023
Thursday, Exelixis Inc (NASDAQ: EXEL) announced that the Alliance for Clinical Trials in Oncology independent Data and Safety Monitoring Board (DSMB) unanimously recommended to unblind and stop the...
Via
Benzinga
2 No-Brainer Biotech Stocks to Buy Right Now
August 24, 2023
These two companies make a compelling case for a high price.
Via
The Motley Fool
These Are the ONLY 3 Biotech Stocks to Consider in August 2023
August 21, 2023
These biotech stocks to buy represent tremendous bets and are essentially fueling innovation and portfolio growth at the same time.
Via
InvestorPlace
Third Time Lucky: Exelixis' Cabozantinib Combo Therapy Aces Pivotal Study In Prostate Cancer Patients
August 21, 2023
Roche Holdings AG (OTC: RHHBY), Exelixis Inc (NASDAQ: EXEL), and Ipsen&nbs
Via
Benzinga
Exelixis Stock Sees Rising Relative Strength Rating
August 14, 2023
On Monday, Exelixis stock hit an key technical milestone, with its Relative Strength Rating rising to 87, an increase from 79 the day before.
Via
Investor's Business Daily
3 Biotech Stocks You’ll Regret Not Buying Soon
August 08, 2023
These top biotech stocks are must-buys with huge potential, leading the industry with high-rewards for investors.
Via
InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2023
August 08, 2023
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.